Margaret R Sketch
Overview
Explore the profile of Margaret R Sketch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
36
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vaidya A, Sketch M, Broderick M, Shlobin O
BMC Pulm Med
. 2024 Nov;
24(1):574.
PMID: 39567921
Background: Current clinical guidelines support use of parenteral prostacyclin therapy for patients with pulmonary arterial hypertension (PAH) at intermediate risk. The objective of this study was to assess parenteral prostacyclin...
2.
Raina A, Sketch M, Wu B, Broderick M, Shlobin O
Pulm Circ
. 2024 Oct;
14(4):e12455.
PMID: 39431235
The objective of this analysis was to compare clinician-based and formally calculated risk assessments by REVEAL Lite 2 and COMPERA 2.0 and to characterize parenteral prostacyclin utilization within 90 days...
3.
Heresi G, Dean B, Wu B, Lee H, Sketch M, Stafkey-Mailey D, et al.
BMC Pulm Med
. 2024 Jul;
24(1):335.
PMID: 38992626
Background: Pulmonary hypertension due to interstitial lung disease (PH-ILD) is associated with high rates of respiratory failure and death. Healthcare resource utilization (HCRU) and cost data are needed to characterize...
4.
Forfia P, Benza R, DAlto M, De Marco T, Elwing J, Frantz R, et al.
Pulm Circ
. 2023 May;
13(2):e12240.
PMID: 37222992
Right heart (RH) structure and function are major determinants of symptoms and prognosis in pulmonary arterial hypertension (PAH). RH imaging provides detailed information, but evidence and guidelines on the use...
5.
Derebail V, Zhu J, Crawford M, Garnier J, Martin K, Skinner S, et al.
Am J Kidney Dis
. 2022 Nov;
81(3):373-376.
PMID: 36328100
No abstract available.
6.
Balasubramanian V, Safdar Z, Sketch M, Broderick M, Nelsen A, Lee D, et al.
Pulm Circ
. 2022 May;
12(1):e12016.
PMID: 35506102
Real-world dosing and titration of parenteral (subcutaneous, SC; intravenous, IV) prostacyclin, a mainstay of pulmonary arterial hypertension (PAH) treatment, is not always consistent with prescribing information or randomized trials and...
7.
Wilson M, Anguiano R, Awdish R, Coons J, Kimber A, Morrison M, et al.
Pulm Circ
. 2022 May;
12(1):e12003.
PMID: 35506067
Mortality in pulmonary arterial hypertension (PAH) remains high and referral to palliative or supportive care (P/SC) specialist services is recommended when appropriate. However, access to P/SC is frequently a challenge...
8.
Heresi G, Dean B, Castillo H, Lee H, Classi P, Stafkey-Mailey D, et al.
Lung
. 2022 Mar;
200(2):187-203.
PMID: 35348836
Background: Group 3 pulmonary hypertension (PH) describes a subpopulation of patients with PH due to chronic lung disease and/or hypoxia, with chronic obstructive pulmonary disease (COPD) and interstitial lung disease...
9.
Szeto A, Bucci T, Deal A, Zhu A, Ahmad M, Cass A, et al.
Ann Pharmacother
. 2021 Sep;
56(7):753-763.
PMID: 34541881
Background: Tyrosine kinase inhibitors (TKIs) are the front-line therapy for chronic myeloid leukemia (CML), where phase 3 clinical trials have demonstrated their safety and efficacy. However, trial patients may not...
10.
Garner L, Kline T, Miller J, Deal A, Zhu A, Sketch M, et al.
J Adv Pract Oncol
. 2021 Feb;
12(1):20-28.
PMID: 33552659
Background: Chronic lymphocytic leukemia (CLL) is a B-cell neoplasm with clonal expansion of small lymphocytes. Ibrutinib, an irreversible inhibitor of Bruton tyrosine kinase (BTK), is a first-line treatment option, and...